Castelvecchio Pascoli (Lucca, Italy), June 9, 2023 – The Board of Directors of Kevlar S.p.A. has approved the unaudited consolidated results for the quarter ended March 31, 2023.
The unaudited financial information presented in this announcement has been derived from the accounting records of Kedrion for the period from January 1, 2023 to March 31, 2023, which are maintained in accordance with IFRS, and from the accounting records of Kedrion and Naga UK Topco Limited for the period from January 1, 2022 to March 31, 2022, which are maintained in accordance with IFRS and UK IFRS, respectively. These preliminary unaudited financial results are subject to change when we finalize the preparation and audit of our accounts for the fiscal year ending December 31, 2023.
This announcement includes certain selected financial highlights but does not constitute an official financial report or presentation to investors. With respect of our H1 2023 results, we will publish an investor presentation and provide an investor call in September. This announcement is solely for information purposes to provide guidance on current business trends.
Revenue increased by €83.6 million, or 39.3%, to €296.1 million for the three months ended March 31, 2023, from €212.5 million for the three months ended March 31, 2022. This increase was mainly driven by the stronger performance in the sale of plasma and Plasma-Derived products.
Reported EBITDA increased by €22.8 million, or 540.1%, to €27.0 million for the three months ended March 31, 2023, from €4.2 million for the three months ended March 31, 2022.
Management Adjusted EBITDA increased by €15.3 million, or 71.9%, to €36.5 million for the three months ended March 31, 2023, from €21.2 million for the three months ended March 31, 2022.
Please click on the links below for additional information on the preliminary unaudited financial results for the quarter ended March 31, 2023 of Kedrion and Kevlar.
This announcement is for information purposes only and does not constitute an offer to sell or the solicitation of an offer to buy securities. This announcement does not contain all of the information that is material to an investor and is not required under the indenture dated May 3, 2023 entered into for the issuance of the 6½% senior secured notes due 2029.
Kedrion is a leading global biopharmaceutical group specializing in the collection and fractionation of human plasma and the development, production and distribution of Plasma-Derived therapeutic products for use in treating serious diseases, disorders and conditions such as hemophilia and immune system deficiencies. Headquartered in Castelvecchio Pascoli (Lucca, Italy), as of March 31, 2023, Kedrion owned and operated 68 collection centers, seven manufacturing facilities and a commercial presence in over 100 countries.
The financial results in this announcement are extracts from the management reporting of Kevlar S.p.A. and its subsidiaries, including Kedrion S.p.A.
For further information, please contact: [email protected].